Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the ...

Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive bladder cancer. The EV-304 (KEYNOTE-B15) trial showed a substantial ...

BEIJING] China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Pfizer (NYSE:PFE) is stepping deeper into the global weight loss race, striking a deal with Hangzhou Sciwind Bioscience for exclusive commercialization rights to ecnoglutide in mainland China, in an ...

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...

Don't follow general market sentiment when it comes to these two stocks.

Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine.

Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new--generation ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM ESTCompany ParticipantsAlbert Bourla - Chairman of the Board ...

The FDA has granted full approval to Pfizer Inc.’s Braftovi when used with Eli Lilly’s Erbitux (cetuximab) and fluorouracil‑based chemotherapy for adults with metastatic colorectal cancer carrying a ...

US pharma giant Pfizer has withdrawn its European application for a marketing authorization of Zumrad (sasanlimab) for the ...